Serina Therapeutics Announces Publication of Invited Feature Article in European Polymer Journal

Huntsville, AL, October 18th, 2016

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development based upon polyoxazoline (POZ™), announced today that the invited article celebrating the 50th anniversary of poly(oxazoline) has been published. The article is entitled “Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications” and is available as a PDF on the company’s website.

“I am delighted to report that our feature article celebrating the 50th anniversary of the first synthesis of poly(oxazoline) has been published online,” said Dr. Moreadith. “This is a significant milestone in the history of this polymer platform, and the article has substantial new information that is now available for the first time. We believe this technology platform is poised to be the next generation in polymer therapeutics.”

SER-214, a once-per-week subcutaneous administration of rotigotine delivered in a standard insulin syringe, is Serina’s most advanced clinical candidate and is currently being studied in a Phase I program in patients suffering from Parkinson’s disease.

In addition to advancing its pipeline programs in pain, oncology, refractory seizures and inflammatory diseases, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and is actively seeking new partnerships.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products
for various pharmaceutical partners. POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus PEG and other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina has partnered its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit www.serinatherapeutics.com.